A novel indium-111-labeled gonadotropin-releasing hormone peptide for human prostate cancer imaging
Identifieur interne : 003492 ( Main/Repository ); précédent : 003491; suivant : 003493A novel indium-111-labeled gonadotropin-releasing hormone peptide for human prostate cancer imaging
Auteurs : RBID : Pascal:12-0204796Descripteurs français
- Pascal (Inist)
- Indium 111, Affinité, Gonadotrophine RH, Souris, Homme, Cancer de la prostate, Agent scintigraphique, Captation, Récepteur hormonal, Voie intraveineuse, Décapeptide, Ligand, Pharmacocinétique, Tomoscintigraphie émission monophotonique, Produit radioisotopique, Hormone peptide, Hormone hypothalamique, Composé couronne azote, Tissu, Distribution, Peptide, Animal, Tétraaza-12-crown-4-tétraacétique acide dérivé, Biodistribution.
- Wicri :
- concept : Homme.
English descriptors
- KwdEn :
- Affinity, Animal, Decapeptide, Distribution, Gonadotropin RH, Hormonal receptor, Human, Hypothalamic hormone, Indium 111, Intravenous administration, Ligand, Mouse, Nitrogen crown compound, Peptide hormone, Peptides, Pharmacokinetics, Prostate cancer, Radioisotopic product, Scintigraphic agent, Single photon emission tomography, Tissue, Uptake.
Abstract
The purpose of this study was to evaluate the tumor targeting and imaging properties of a novel 111In-labeled gonadotropin-releasing hormone (GnRH) peptide {1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA)-Ahx-(D-Lys6-GnRH1)} for human prostate cancer. The biodistribution and tumor imaging properties of 111In-DOTA-Ahx-(D-Lys6-GnRH1) were determined in DU145 human prostate cancer-xenografted nude mice. 111In-DOTA-Ahx-(D-Lys6-GnRH1) exhibited rapid tumor uptake (1.27 ± 0.40% ID/g at 0.5 h post-injection) coupled with fast whole-body clearance through the urinary system. The DU145 human prostate cancer-xenografted tumor lesions were clearly visualized by single photon emission computed tomography (SPECT)/CT at 0.5 h post-injection of 111In-DOTA-Ahx-(D-Lys6-GnRH1). The successful imaging of DU145 human prostate cancer-xenografted tumor lesions using 111In-DOTA-Ahx-(D-Lys6-GnRH1) highlighted its potential as a novel imaging probe for human prostate cancer imaging.
Links toward previous steps (curation, corpus...)
- to stream Main, to step Corpus: 001E16
Links to Exploration step
Pascal:12-0204796Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">A novel indium-111-labeled gonadotropin-releasing hormone peptide for human prostate cancer imaging</title><author><name>HAIXUN GUO</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>College of Pharmacy, University of New Mexico, Albuquerque</s1><s2>NM 87131</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>4 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Nouveau-Mexique</region></placeName></affiliation></author><author><name sortKey="Gallazzi, Fabio" uniqKey="Gallazzi F">Fabio Gallazzi</name><affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Department of Biochemistry, University of Missouri</s1><s2>Columbia, MO 65211</s2><s3>USA</s3><sZ>2 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>Columbia, MO 65211</wicri:noRegion></affiliation></author><author><name sortKey="Sklar, Larry A" uniqKey="Sklar L">Larry A. Sklar</name><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Cancer Research and Treatment Center, University of New Mexico</s1><s2>Albuquerque, NM 87131</s2><s3>USA</s3><sZ>3 aut.</sZ><sZ>4 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>Albuquerque, NM 87131</wicri:noRegion></affiliation><affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Department of Pathology, University of New Mexico</s1><s2>Albuquerque, NM 87131</s2><s3>USA</s3><sZ>3 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>Albuquerque, NM 87131</wicri:noRegion></affiliation></author><author><name sortKey="Miao, Yubin" uniqKey="Miao Y">Yubin Miao</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>College of Pharmacy, University of New Mexico, Albuquerque</s1><s2>NM 87131</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>4 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Nouveau-Mexique</region></placeName></affiliation><affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Cancer Research and Treatment Center, University of New Mexico</s1><s2>Albuquerque, NM 87131</s2><s3>USA</s3><sZ>3 aut.</sZ><sZ>4 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>Albuquerque, NM 87131</wicri:noRegion></affiliation><affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Department of Dermatology, University of New Mexico</s1><s2>Albuquerque, NM 87131</s2><s3>USA</s3><sZ>4 aut.</sZ></inist:fA14><country>États-Unis</country><wicri:noRegion>Albuquerque, NM 87131</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="inist">12-0204796</idno><date when="2011">2011</date><idno type="stanalyst">PASCAL 12-0204796 INIST</idno><idno type="RBID">Pascal:12-0204796</idno><idno type="wicri:Area/Main/Corpus">001E16</idno><idno type="wicri:Area/Main/Repository">003492</idno></publicationStmt><seriesStmt><idno type="ISSN">0960-894X</idno><title level="j" type="abbreviated">Bioorg. med. chem. lett. : (Print)</title><title level="j" type="main">Bioorganic & medicinal chemistry letters : (Print)</title></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Affinity</term><term>Animal</term><term>Decapeptide</term><term>Distribution</term><term>Gonadotropin RH</term><term>Hormonal receptor</term><term>Human</term><term>Hypothalamic hormone</term><term>Indium 111</term><term>Intravenous administration</term><term>Ligand</term><term>Mouse</term><term>Nitrogen crown compound</term><term>Peptide hormone</term><term>Peptides</term><term>Pharmacokinetics</term><term>Prostate cancer</term><term>Radioisotopic product</term><term>Scintigraphic agent</term><term>Single photon emission tomography</term><term>Tissue</term><term>Uptake</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Indium 111</term><term>Affinité</term><term>Gonadotrophine RH</term><term>Souris</term><term>Homme</term><term>Cancer de la prostate</term><term>Agent scintigraphique</term><term>Captation</term><term>Récepteur hormonal</term><term>Voie intraveineuse</term><term>Décapeptide</term><term>Ligand</term><term>Pharmacocinétique</term><term>Tomoscintigraphie émission monophotonique</term><term>Produit radioisotopique</term><term>Hormone peptide</term><term>Hormone hypothalamique</term><term>Composé couronne azote</term><term>Tissu</term><term>Distribution</term><term>Peptide</term><term>Animal</term><term>Tétraaza-12-crown-4-tétraacétique acide dérivé</term><term>Biodistribution</term></keywords><keywords scheme="Wicri" type="concept" xml:lang="fr"><term>Homme</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The purpose of this study was to evaluate the tumor targeting and imaging properties of a novel 111In-labeled gonadotropin-releasing hormone (GnRH) peptide {1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA)-Ahx-(D-Lys6-GnRH1)} for human prostate cancer. The biodistribution and tumor imaging properties of 111In-DOTA-Ahx-(D-Lys6-GnRH1) were determined in DU145 human prostate cancer-xenografted nude mice. 111In-DOTA-Ahx-(D-Lys6-GnRH1) exhibited rapid tumor uptake (1.27 ± 0.40% ID/g at 0.5 h post-injection) coupled with fast whole-body clearance through the urinary system. The DU145 human prostate cancer-xenografted tumor lesions were clearly visualized by single photon emission computed tomography (SPECT)/CT at 0.5 h post-injection of 111In-DOTA-Ahx-(D-Lys6-GnRH1). The successful imaging of DU145 human prostate cancer-xenografted tumor lesions using 111In-DOTA-Ahx-(D-Lys6-GnRH1) highlighted its potential as a novel imaging probe for human prostate cancer imaging.</div></front></TEI><inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0960-894X</s0></fA01><fA03 i2="1"><s0>Bioorg. med. chem. lett. : (Print)</s0></fA03><fA05><s2>21</s2></fA05><fA06><s2>18</s2></fA06><fA08 i1="01" i2="1" l="ENG"><s1>A novel indium-111-labeled gonadotropin-releasing hormone peptide for human prostate cancer imaging</s1></fA08><fA11 i1="01" i2="1"><s1>HAIXUN GUO</s1></fA11><fA11 i1="02" i2="1"><s1>GALLAZZI (Fabio)</s1></fA11><fA11 i1="03" i2="1"><s1>SKLAR (Larry A.)</s1></fA11><fA11 i1="04" i2="1"><s1>MIAO (Yubin)</s1></fA11><fA14 i1="01"><s1>College of Pharmacy, University of New Mexico, Albuquerque</s1><s2>NM 87131</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>4 aut.</sZ></fA14><fA14 i1="02"><s1>Cancer Research and Treatment Center, University of New Mexico</s1><s2>Albuquerque, NM 87131</s2><s3>USA</s3><sZ>3 aut.</sZ><sZ>4 aut.</sZ></fA14><fA14 i1="03"><s1>Department of Dermatology, University of New Mexico</s1><s2>Albuquerque, NM 87131</s2><s3>USA</s3><sZ>4 aut.</sZ></fA14><fA14 i1="04"><s1>Department of Pathology, University of New Mexico</s1><s2>Albuquerque, NM 87131</s2><s3>USA</s3><sZ>3 aut.</sZ></fA14><fA14 i1="05"><s1>Department of Biochemistry, University of Missouri</s1><s2>Columbia, MO 65211</s2><s3>USA</s3><sZ>2 aut.</sZ></fA14><fA20><s1>5184-5187</s1></fA20><fA21><s1>2011</s1></fA21><fA23 i1="01"><s0>ENG</s0></fA23><fA43 i1="01"><s1>INIST</s1><s2>22446</s2><s5>354000509110730100</s5></fA43><fA44><s0>0000</s0><s1>© 2012 INIST-CNRS. All rights reserved.</s1></fA44><fA45><s0>36 ref.</s0></fA45><fA47 i1="01" i2="1"><s0>12-0204796</s0></fA47><fA60><s1>P</s1></fA60><fA61><s0>A</s0></fA61><fA64 i1="01" i2="1"><s0>Bioorganic & medicinal chemistry letters : (Print)</s0></fA64><fA66 i1="01"><s0>NLD</s0></fA66><fC01 i1="01" l="ENG"><s0>The purpose of this study was to evaluate the tumor targeting and imaging properties of a novel 111In-labeled gonadotropin-releasing hormone (GnRH) peptide {1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA)-Ahx-(D-Lys6-GnRH1)} for human prostate cancer. The biodistribution and tumor imaging properties of 111In-DOTA-Ahx-(D-Lys6-GnRH1) were determined in DU145 human prostate cancer-xenografted nude mice. 111In-DOTA-Ahx-(D-Lys6-GnRH1) exhibited rapid tumor uptake (1.27 ± 0.40% ID/g at 0.5 h post-injection) coupled with fast whole-body clearance through the urinary system. The DU145 human prostate cancer-xenografted tumor lesions were clearly visualized by single photon emission computed tomography (SPECT)/CT at 0.5 h post-injection of 111In-DOTA-Ahx-(D-Lys6-GnRH1). The successful imaging of DU145 human prostate cancer-xenografted tumor lesions using 111In-DOTA-Ahx-(D-Lys6-GnRH1) highlighted its potential as a novel imaging probe for human prostate cancer imaging.</s0></fC01><fC02 i1="01" i2="X"><s0>002B02T</s0></fC02><fC03 i1="01" i2="3" l="FRE"><s0>Indium 111</s0><s5>01</s5></fC03><fC03 i1="01" i2="3" l="ENG"><s0>Indium 111</s0><s5>01</s5></fC03><fC03 i1="02" i2="X" l="FRE"><s0>Affinité</s0><s5>02</s5></fC03><fC03 i1="02" i2="X" l="ENG"><s0>Affinity</s0><s5>02</s5></fC03><fC03 i1="02" i2="X" l="SPA"><s0>Afinidad</s0><s5>02</s5></fC03><fC03 i1="03" i2="X" l="FRE"><s0>Gonadotrophine RH</s0><s5>03</s5></fC03><fC03 i1="03" i2="X" l="ENG"><s0>Gonadotropin RH</s0><s5>03</s5></fC03><fC03 i1="03" i2="X" l="SPA"><s0>Gonadotropina RH</s0><s5>03</s5></fC03><fC03 i1="04" i2="X" l="FRE"><s0>Souris</s0><s5>04</s5></fC03><fC03 i1="04" i2="X" l="ENG"><s0>Mouse</s0><s5>04</s5></fC03><fC03 i1="04" i2="X" l="SPA"><s0>Ratón</s0><s5>04</s5></fC03><fC03 i1="05" i2="X" l="FRE"><s0>Homme</s0><s5>05</s5></fC03><fC03 i1="05" i2="X" l="ENG"><s0>Human</s0><s5>05</s5></fC03><fC03 i1="05" i2="X" l="SPA"><s0>Hombre</s0><s5>05</s5></fC03><fC03 i1="06" i2="X" l="FRE"><s0>Cancer de la prostate</s0><s2>NM</s2><s5>06</s5></fC03><fC03 i1="06" i2="X" l="ENG"><s0>Prostate cancer</s0><s2>NM</s2><s5>06</s5></fC03><fC03 i1="06" i2="X" l="SPA"><s0>Cáncer de la próstata</s0><s2>NM</s2><s5>06</s5></fC03><fC03 i1="07" i2="X" l="FRE"><s0>Agent scintigraphique</s0><s5>07</s5></fC03><fC03 i1="07" i2="X" l="ENG"><s0>Scintigraphic agent</s0><s5>07</s5></fC03><fC03 i1="07" i2="X" l="SPA"><s0>Agente centelleográfico</s0><s5>07</s5></fC03><fC03 i1="08" i2="X" l="FRE"><s0>Captation</s0><s5>08</s5></fC03><fC03 i1="08" i2="X" l="ENG"><s0>Uptake</s0><s5>08</s5></fC03><fC03 i1="08" i2="X" l="SPA"><s0>Captación</s0><s5>08</s5></fC03><fC03 i1="09" i2="X" l="FRE"><s0>Récepteur hormonal</s0><s5>09</s5></fC03><fC03 i1="09" i2="X" l="ENG"><s0>Hormonal receptor</s0><s5>09</s5></fC03><fC03 i1="09" i2="X" l="SPA"><s0>Receptor hormonal</s0><s5>09</s5></fC03><fC03 i1="10" i2="X" l="FRE"><s0>Voie intraveineuse</s0><s5>10</s5></fC03><fC03 i1="10" i2="X" l="ENG"><s0>Intravenous administration</s0><s5>10</s5></fC03><fC03 i1="10" i2="X" l="SPA"><s0>Vía intravenosa</s0><s5>10</s5></fC03><fC03 i1="11" i2="X" l="FRE"><s0>Décapeptide</s0><s5>11</s5></fC03><fC03 i1="11" i2="X" l="ENG"><s0>Decapeptide</s0><s5>11</s5></fC03><fC03 i1="11" i2="X" l="SPA"><s0>Decapéptido</s0><s5>11</s5></fC03><fC03 i1="12" i2="X" l="FRE"><s0>Ligand</s0><s5>12</s5></fC03><fC03 i1="12" i2="X" l="ENG"><s0>Ligand</s0><s5>12</s5></fC03><fC03 i1="12" i2="X" l="SPA"><s0>Ligando</s0><s5>12</s5></fC03><fC03 i1="13" i2="X" l="FRE"><s0>Pharmacocinétique</s0><s5>13</s5></fC03><fC03 i1="13" i2="X" l="ENG"><s0>Pharmacokinetics</s0><s5>13</s5></fC03><fC03 i1="13" i2="X" l="SPA"><s0>Farmacocinética</s0><s5>13</s5></fC03><fC03 i1="14" i2="X" l="FRE"><s0>Tomoscintigraphie émission monophotonique</s0><s5>14</s5></fC03><fC03 i1="14" i2="X" l="ENG"><s0>Single photon emission tomography</s0><s5>14</s5></fC03><fC03 i1="14" i2="X" l="SPA"><s0>Tomografía emisión fotón único</s0><s5>14</s5></fC03><fC03 i1="15" i2="X" l="FRE"><s0>Produit radioisotopique</s0><s5>32</s5></fC03><fC03 i1="15" i2="X" l="ENG"><s0>Radioisotopic product</s0><s5>32</s5></fC03><fC03 i1="15" i2="X" l="SPA"><s0>Producto radioisotópico</s0><s5>32</s5></fC03><fC03 i1="16" i2="X" l="FRE"><s0>Hormone peptide</s0><s5>33</s5></fC03><fC03 i1="16" i2="X" l="ENG"><s0>Peptide hormone</s0><s5>33</s5></fC03><fC03 i1="16" i2="X" l="SPA"><s0>Hormona péptido</s0><s5>33</s5></fC03><fC03 i1="17" i2="X" l="FRE"><s0>Hormone hypothalamique</s0><s5>34</s5></fC03><fC03 i1="17" i2="X" l="ENG"><s0>Hypothalamic hormone</s0><s5>34</s5></fC03><fC03 i1="17" i2="X" l="SPA"><s0>Hormona hipotalámica</s0><s5>34</s5></fC03><fC03 i1="18" i2="X" l="FRE"><s0>Composé couronne azote</s0><s5>35</s5></fC03><fC03 i1="18" i2="X" l="ENG"><s0>Nitrogen crown compound</s0><s5>35</s5></fC03><fC03 i1="18" i2="X" l="SPA"><s0>Compuesto corona nitrógeno</s0><s5>35</s5></fC03><fC03 i1="19" i2="X" l="FRE"><s0>Tissu</s0><s5>36</s5></fC03><fC03 i1="19" i2="X" l="ENG"><s0>Tissue</s0><s5>36</s5></fC03><fC03 i1="19" i2="X" l="SPA"><s0>Tejido</s0><s5>36</s5></fC03><fC03 i1="20" i2="X" l="FRE"><s0>Distribution</s0><s5>37</s5></fC03><fC03 i1="20" i2="X" l="ENG"><s0>Distribution</s0><s5>37</s5></fC03><fC03 i1="20" i2="X" l="SPA"><s0>Distribución</s0><s5>37</s5></fC03><fC03 i1="21" i2="X" l="FRE"><s0>Peptide</s0><s5>38</s5></fC03><fC03 i1="21" i2="X" l="ENG"><s0>Peptides</s0><s5>38</s5></fC03><fC03 i1="21" i2="X" l="SPA"><s0>Péptido</s0><s5>38</s5></fC03><fC03 i1="22" i2="X" l="FRE"><s0>Animal</s0><s5>39</s5></fC03><fC03 i1="22" i2="X" l="ENG"><s0>Animal</s0><s5>39</s5></fC03><fC03 i1="22" i2="X" l="SPA"><s0>Animal</s0><s5>39</s5></fC03><fC03 i1="23" i2="X" l="FRE"><s0>Tétraaza-12-crown-4-tétraacétique acide dérivé</s0><s2>NK</s2><s4>INC</s4><s5>76</s5></fC03><fC03 i1="24" i2="X" l="FRE"><s0>Biodistribution</s0><s4>INC</s4><s5>77</s5></fC03><fC07 i1="01" i2="X" l="FRE"><s0>Rodentia</s0><s2>NS</s2></fC07><fC07 i1="01" i2="X" l="ENG"><s0>Rodentia</s0><s2>NS</s2></fC07><fC07 i1="01" i2="X" l="SPA"><s0>Rodentia</s0><s2>NS</s2></fC07><fC07 i1="02" i2="X" l="FRE"><s0>Mammalia</s0><s2>NS</s2></fC07><fC07 i1="02" i2="X" l="ENG"><s0>Mammalia</s0><s2>NS</s2></fC07><fC07 i1="02" i2="X" l="SPA"><s0>Mammalia</s0><s2>NS</s2></fC07><fC07 i1="03" i2="X" l="FRE"><s0>Vertebrata</s0><s2>NS</s2></fC07><fC07 i1="03" i2="X" l="ENG"><s0>Vertebrata</s0><s2>NS</s2></fC07><fC07 i1="03" i2="X" l="SPA"><s0>Vertebrata</s0><s2>NS</s2></fC07><fC07 i1="04" i2="X" l="FRE"><s0>Pathologie de l'appareil génital mâle</s0><s5>53</s5></fC07><fC07 i1="04" i2="X" l="ENG"><s0>Male genital diseases</s0><s5>53</s5></fC07><fC07 i1="04" i2="X" l="SPA"><s0>Aparato genital macho patología</s0><s5>53</s5></fC07><fC07 i1="05" i2="X" l="FRE"><s0>Pathologie de l'appareil urinaire</s0><s5>54</s5></fC07><fC07 i1="05" i2="X" l="ENG"><s0>Urinary system disease</s0><s5>54</s5></fC07><fC07 i1="05" i2="X" l="SPA"><s0>Aparato urinario patología</s0><s5>54</s5></fC07><fC07 i1="06" i2="X" l="FRE"><s0>Pathologie de la prostate</s0><s5>55</s5></fC07><fC07 i1="06" i2="X" l="ENG"><s0>Prostate disease</s0><s5>55</s5></fC07><fC07 i1="06" i2="X" l="SPA"><s0>Prostata patología</s0><s5>55</s5></fC07><fC07 i1="07" i2="X" l="FRE"><s0>Tumeur maligne</s0><s2>NM</s2><s5>56</s5></fC07><fC07 i1="07" i2="X" l="ENG"><s0>Malignant tumor</s0><s2>NM</s2><s5>56</s5></fC07><fC07 i1="07" i2="X" l="SPA"><s0>Tumor maligno</s0><s2>NM</s2><s5>56</s5></fC07><fC07 i1="08" i2="X" l="FRE"><s0>Cancer</s0><s2>NM</s2></fC07><fC07 i1="08" i2="X" l="ENG"><s0>Cancer</s0><s2>NM</s2></fC07><fC07 i1="08" i2="X" l="SPA"><s0>Cáncer</s0><s2>NM</s2></fC07><fN21><s1>156</s1></fN21></pA></standard></inist></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=IndiumV3/Data/Main/Repository
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003492 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Repository/biblio.hfd -nk 003492 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= *** parameter Area/wikiCode missing ***
|area= IndiumV3
|flux= Main
|étape= Repository
|type= RBID
|clé= Pascal:12-0204796
|texte= A novel indium-111-labeled gonadotropin-releasing hormone peptide for human prostate cancer imaging
}}
| This area was generated with Dilib version V0.5.77. |  |